RxDoctor Payments Data

Jolan Cruzado

Nurse Practitioner · Tallahassee, FLNPI 1518486307

Payments from drug & device makers

$1,929in general payments, 2019–2025

Across 78 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$400
  • Sumitomo Pharma America, Inc.$236
  • Coloplast$199
  • Astellas Pharma US Inc$186
  • Johnson & Johnson$140
  • Ferring Pharmaceuticals Inc.$124
  • plus $644 from 15 others

What the payments were for

  • Food & beverage$1,82995%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,929 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$35,369
Medicare patients
193
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron116$108,592
MyrbetriqMirabegron131$84,377
Trospium Chloride ErTrospium Chloride25$5,532
Tamsulosin Hcl227$3,443
Trimethoprim45$2,796
Estradiol42$2,711
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst86$2,545
Finasteride127$1,802
Cephalexin58$987
NitrofurantoinNitrofurantoin Macrocrystal13$939
Solifenacin Succinate30$907
Tetracycline Hcl26$801
Doxycycline Monohydrate32$459
Cefpodoxime Proxetil12$422
Levofloxacin74$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$236$108,592116 claims
Astellas Pharma US IncMyrbetriq$186$84,377131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →